A 72-year-old woman from Mumbai with a 10-year history of hypertension and diabetes presents with progressive dyspnea, fatigue, and ankle swelling for 6 weeks. On examination: BP 145/92 mmHg, HR 88/min regular, JVP 6 cm, no S3 gallop, lungs clear to auscultation bilaterally. Echocardiography shows LVEF 52%, LV wall thickness 14 mm, LA enlargement, and restrictive mitral inflow pattern (E/A ratio 2.2, E/e' ratio 14). Which of the following is the most likely diagnosis?

Explanation

## Clinical Presentation Analysis ### Key Diagnostic Features | Feature | Finding | Significance | |---|---|---| | **LVEF** | 52% | ≥ 50% = Preserved EF | | **LV Wall Thickness** | 14 mm | Increased (normal < 11 mm); suggests LVH | | **LA Enlargement** | Present | Chronic elevation of LV filling pressures | | **Mitral Inflow Pattern** | E/A = 2.2 (E > A) | Restrictive/impaired relaxation pattern | | **E/e' Ratio** | 14 | ≥ 14 indicates elevated LV filling pressures | | **S3 Gallop** | Absent | Argues against systolic HF | | **Lung Auscultation** | Clear | No pulmonary edema clinically | | **Risk Factors** | HTN, DM × 10 years | Classic for diastolic dysfunction | ## Diagnosis: HFpEF (Diastolic Heart Failure) **Key Point:** This patient meets diagnostic criteria for **heart failure with preserved ejection fraction (HFpEF)**, also called diastolic heart failure: 1. **Symptoms and signs of HF** (dyspnea, fatigue, ankle edema, elevated JVP) 2. **LVEF ≥ 50%** (preserved systolic function) 3. **Evidence of diastolic dysfunction:** - Restrictive mitral inflow (E/A > 1 in restrictive pattern) - Elevated E/e' ratio (≥ 14 = elevated LV filling pressure) - LA enlargement (chronic pressure overload) - LVH (from chronic hypertension) **High-Yield:** HFpEF accounts for **40–50% of all HF cases**, particularly in elderly women with hypertension and diabetes. The diagnosis requires **both** clinical HF symptoms AND evidence of diastolic dysfunction on echo. ## Pathophysiology of HFpEF ```mermaid flowchart TD A[Chronic Hypertension + Diabetes]:::outcome --> B[Increased Afterload + Metabolic Stress]:::outcome B --> C[LV Concentric Hypertrophy]:::outcome C --> D[Impaired LV Relaxation]:::outcome D --> E[Increased LV Stiffness]:::outcome E --> F[Elevated LV Filling Pressures]:::outcome F --> G[LA Enlargement]:::outcome G --> H[Atrial Fibrillation Risk]:::urgent F --> I[Pulmonary Congestion]:::outcome I --> J[Dyspnea, Orthopnea]:::outcome E --> K[Restrictive Mitral Inflow E/A > 1]:::outcome ``` **Clinical Pearl:** In HFpEF, the problem is NOT weak contraction (systolic function is normal) but STIFF ventricles that don't relax well (diastolic dysfunction). This explains why inotropes and ACE-I have limited benefit. ## Why Other Options Are Incorrect ### Option 1: HFrEF - **LVEF is 52% (≥ 50%)**, which is preserved, not reduced - HFrEF is defined as LVEF ≤ 40%; this patient's EF is normal - No S3 gallop (typical in HFrEF) - **Trap:** Some students confuse "heart failure" with "reduced EF" — HFpEF is equally common ### Option 3: Restrictive Cardiomyopathy (Amyloidosis) While the restrictive mitral inflow pattern (E/A > 1) might suggest restriction, several features argue against primary restrictive cardiomyopathy: - **LVH pattern** (14 mm wall thickness) is typical of hypertensive LVH, not amyloidosis - **Risk factors** (HTN, DM) point to secondary diastolic dysfunction, not primary myocardial disease - **No systemic symptoms** (no weight loss, neuropathy, hepatomegaly mentioned) - **LA enlargement alone** is common in HFpEF from HTN; it is not specific for amyloidosis - Amyloidosis typically presents with **biventricular involvement, conduction abnormalities, and low voltage on ECG** (not mentioned here) **Warning:** Restrictive cardiomyopathy is a diagnosis of exclusion; it requires ruling out secondary causes (HTN, infiltrative disease) first. ### Option 4: Acute Decompensation from ACS - **No acute presentation** (6-week gradual onset, not acute chest pain) - **No ECG changes or troponin elevation** mentioned - **HR is regular at 88/min** (no arrhythmia) - **No acute coronary risk profile** described - This is a chronic, progressive picture, not acute decompensation ## Diagnostic Criteria for HFpEF (ESC 2021) **All three required:** 1. Symptoms ± signs of HF 2. LVEF ≥ 50% 3. **At least one of:** - Elevated natriuretic peptides (BNP > 35 pg/mL or NT-proBNP > 125 pg/mL) - Diastolic dysfunction on echo (E/e' ≥ 14, LA volume index > 34 mL/m²) - Elevated LV filling pressures on catheterization **Mnemonic for HFpEF Features:** **"STIFF Ventricle"** - **S**ystolic function normal (EF ≥ 50%) - **T**hick walls (LVH from HTN) - **I**mpaired relaxation (E/A > 1 in restrictive pattern) - **F**illing pressures elevated (E/e' ≥ 14) - **F**unctional limitation (dyspnea, fatigue) ## Management Implications **Key Point:** HFpEF management differs from HFrEF: - **No mortality benefit** from ACE-I, beta-blockers, or aldosterone antagonists (unlike HFrEF) - **Diuretics** for symptom relief - **BP control** (target < 130/80 mmHg) - **Treat comorbidities** (HTN, DM, AF) - **SGLT2 inhibitors** (empagliflozin, dapagliflozin) show promise in recent trials - **Avoid excessive diuresis** (preload-dependent in diastolic dysfunction)